Manufacturing cost reduction
Make the cost of making medicine visible. Explore equipment, process and production trade-offs in an open cost model.
Building open tools for pharmaceutical research, evidence and manufacturing. A shared foundation for a future where more people can access the medicine they need.
Early-stage project. Built in the open.
All six modules are at the planning stage. Progress will reflect completed, documented milestones.
Each module has its own Phase 0–5 strategy, acceptance criteria, public changelog and future product portal.
Make the cost of making medicine visible. Explore equipment, process and production trade-offs in an open cost model.
Design a modular research workspace. Bring equipment specifications, workflow software and reproducible experiments together.
Connect the evidence workflow end to end, from literature and protocol drafts to analysis and reporting, with expert review at each decision.
Explore promising research directions with transparent models. Connect targets, molecular data and computational screening in one workflow.
Investigate new research uses for existing medicines. Map drug, target and disease evidence to surface hypotheses worth testing.
Give others a starting point they can reproduce. Catalogue datasets, models and experiments with provenance, licences and setup instructions.
These are planned capabilities. Research outputs will need appropriate expert review and experimental validation.
Six phases from product 0 to 1.0. Each module defines the work and acceptance criteria behind these milestones.
Define the question, scope and acceptance criteria.
Pin inputs, sources and reproducibility requirements.
Build one usable workflow from input to output.
Evaluate held-out cases and publish limitations.
Test the workflow with qualified partners.
Release supported tools with maintenance plans.
Phase 0 is the starting point at 0%; Phase 5 is product 1.0 at 100%. Publishing plans does not advance product completion. Percentages represent development milestones, not clinical validation or regulatory approval. Overall progress is the equal-weight average of the six modules.
OpenPharma starts with a question: what becomes possible when the tools behind medicine are easier to inspect, reproduce and improve?
The ambition is more accessible medicine. The work starts with open software, transparent methods and a public record of what works, what fails and what comes next.
Follow the workA capstone project by Edozie. Follow the decisions, experiments and milestones from the first prototype onward.
Created a public code fork of rdkit/rdkit with the upstream BSD 3-Clause licence retained. This establishes a software starting point; no dataset mirror, benchmark result or completed product milestone is claimed.
Created a public code fork of deepchem/deepchem with its upstream MIT licence retained. No OpenPharma model training, dataset mirroring or benchmark validation has been completed.
Published the module strategy, concrete phase deliverables, acceptance criteria and future portal workflow. This is a planning update; product completion remains 0%.